JP2023537958A5 - - Google Patents
Info
- Publication number
- JP2023537958A5 JP2023537958A5 JP2023509554A JP2023509554A JP2023537958A5 JP 2023537958 A5 JP2023537958 A5 JP 2023537958A5 JP 2023509554 A JP2023509554 A JP 2023509554A JP 2023509554 A JP2023509554 A JP 2023509554A JP 2023537958 A5 JP2023537958 A5 JP 2023537958A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable domain
- single variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010842370 | 2020-08-20 | ||
| CN202010842370.5 | 2020-08-20 | ||
| PCT/CN2021/112756 WO2022037527A1 (zh) | 2020-08-20 | 2021-08-16 | 结合bcma的单可变结构域及抗原结合分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537958A JP2023537958A (ja) | 2023-09-06 |
| JP2023537958A5 true JP2023537958A5 (https=) | 2024-08-26 |
| JP7821159B2 JP7821159B2 (ja) | 2026-02-26 |
Family
ID=80323410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509554A Active JP7821159B2 (ja) | 2020-08-20 | 2021-08-16 | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12612635B2 (https=) |
| EP (1) | EP4202047A4 (https=) |
| JP (1) | JP7821159B2 (https=) |
| KR (1) | KR20230045066A (https=) |
| CN (1) | CN115715325A (https=) |
| WO (1) | WO2022037527A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002066516A2 (en) * | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| EP3974453A3 (en) * | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| US9243058B2 (en) * | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| KR102526945B1 (ko) * | 2014-04-30 | 2023-04-27 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
| US10294304B2 (en) * | 2015-04-13 | 2019-05-21 | Pfizer Inc. | Chimeric antigen receptors targeting B-cell maturation antigen |
| WO2018028647A1 (en) | 2016-08-10 | 2018-02-15 | Legend Biotech Usa Inc. | Chimeric antigen receptors targeting bcma and methods of use thereof |
| CN111201243B (zh) * | 2017-09-29 | 2023-08-11 | 财团法人牧岩生命科学研究所 | 对bcma具有高亲和力的抗bcma抗体和包含其的用于治疗癌症的药物组合物 |
| KR102870868B1 (ko) | 2018-06-01 | 2025-10-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| EP3845244A4 (en) * | 2018-08-24 | 2022-09-07 | Shenzhen Pregene Biopharma Co. Ltd. | ANTI-BCMA SINGLE DOMAIN ANTIBODIES AND THEIR USE |
| CN109942708B (zh) * | 2019-03-28 | 2021-01-05 | 上海科棋药业科技有限公司 | 一种抗bcma的单域抗体及其应用 |
| CN109942709B (zh) * | 2019-04-22 | 2019-12-27 | 广州百暨基因科技有限公司 | 一种抗bcma的单域抗体及其应用 |
| CN111333729B (zh) * | 2020-03-17 | 2022-12-06 | 深圳市南科生物工程有限公司 | 抗b细胞成熟抗原的纳米抗体及应用 |
| WO2022218380A1 (zh) | 2021-04-15 | 2022-10-20 | 正大天晴药业集团股份有限公司 | 靶向bcma的多特异性抗体 |
-
2021
- 2021-08-16 US US18/020,578 patent/US12612635B2/en active Active
- 2021-08-16 KR KR1020237007603A patent/KR20230045066A/ko active Pending
- 2021-08-16 WO PCT/CN2021/112756 patent/WO2022037527A1/zh not_active Ceased
- 2021-08-16 JP JP2023509554A patent/JP7821159B2/ja active Active
- 2021-08-16 CN CN202180041380.1A patent/CN115715325A/zh active Pending
- 2021-08-16 EP EP21857622.1A patent/EP4202047A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023537958A5 (https=) | ||
| JP2019536430A5 (https=) | ||
| JP2021516976A5 (https=) | ||
| JP2023526774A5 (https=) | ||
| JP2024167313A5 (https=) | ||
| JP2023509196A5 (https=) | ||
| JP2020525032A5 (https=) | ||
| JP2021515566A5 (https=) | ||
| JP2020023523A5 (https=) | ||
| JP2024062992A5 (https=) | ||
| JP2021516975A5 (https=) | ||
| JP2020506898A5 (https=) | ||
| JP2011509245A5 (https=) | ||
| JP2020195399A5 (https=) | ||
| JP2019501883A5 (https=) | ||
| JP2023543493A5 (https=) | ||
| CN111201238B (zh) | 产生多特异性抗体混合物及其使用方法 | |
| RU2010100638A (ru) | Композиции и способы лечения, направленные против cd20 | |
| JPWO2015146437A1 (ja) | 高機能性ＩｇＧ２型二重特異性抗体 | |
| JP2018537421A5 (https=) | ||
| CN102421802A (zh) | 人源化的axl抗体 | |
| WO2019196309A1 (zh) | 抗pd-l1抗体及其用途 | |
| JPWO2020059847A5 (https=) | ||
| CN105837688A (zh) | 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞 | |
| JP2021522303A5 (https=) |